Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival

SpringerPlus

Volumn 4, Issue 1, 2015, Pages

  Eremin, Jennifer ^a   Cowley, Ged ^a   Walker, Leslie G ^b   Murray, Elisabeth ^a   Stovickova, Monika ^a   Eremin, Oleg ^a,c  

^a LINCOLN COUNTY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Response; Survival

Indexed keywords

EID: 84929192841     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-4-9     Document Type: Article

References (47)

1. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27.J Clin Oncol 2006,24(13):2019–2027. 10.1200/JCO.2005.04.1665
2. Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N: Bevacizumab added to neoadjuvant chemotherapy for breast cancer.N Engl J Med 2012,366(4):310–320. 10.1056/NEJMoa1111097
3. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G: Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument.J Clin Oncol 1997,15(3):974–986.
4. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res 2007,13(8):2329–2334. 10.1158/1078-0432.CCR-06-1109
5. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.Cancer 1989,63(1):181–187. Publisher Full Text 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
6. Colleoni M, Goldhirsch A: Neoadjuvant chemotherapy for breast cancer: any progress?Lancet Oncol 2014,15(2):131–132. 10.1016/S1470-2045(13)70584-9
7. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nole F, Peruzzotti G, Goldhirsch A: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.Clin Cancer Res 2004,10(19):6622–6628. 10.1158/1078-0432.CCR-04-0380
8. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence.Clin Cancer Res 2007,13(15 Pt 1):4429–4434.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer 2009,45(2):228–247. 10.1016/j.ejca.2008.10.026
10. Fisher CS, Cole DJ, Mitas M, Garrett-Meyer E, Metcalf JS, Gillanders WE, Mikhitarian K, Urist MM, Mann GB, Doherty G, Herrmann VM, Hill AD, Eremin O, El-Sheemy M, Orr RK, Valle AA, Henderson MA, Dewitty RL, Sugg SL, Frykberg E, Yeh K, Bell RM, Baker MK: Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes fails to predict breast cancer recurrence: a final analysis of a prospective multi-institutional cohort study.Ann Surg Oncol 2010,17(Suppl 3):312–320.
11. Gluck S, Russell C, O'Shaughnessy J, McKenna EF, Hu S, Odom D, Blum JL: Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis.Breast 2013,22(6):1087–1093. 10.1016/j.breast.2013.08.016
12. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V: Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.J Clin Oncol 2005,23(36):9304–9311. 10.1200/JCO.2005.02.5023
13. Jiang Y, Yin W, Zhou L, Yan T, Zhou Q, Du Y, Shen Z, Shao Z, Lu J: First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.PLoS One 2012,7(3):e32474. 10.1371/journal.pone.0032474
14. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, Villman K, Nyandoto P, Nilsson G, Pajunen M, Asola R, Poikonen P, Leinonen M, Kataja V, Bono P, Lindman H: Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.J Clin Oncol 2012,30(1):11–18. 10.1200/JCO.2011.35.4639
15. Jones RL, Lakhani SR, Ring AE, Ashley S, Walsh G, Smith IE: Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma.Br J Cancer 2006,94(3):358–362. 10.1038/sj.bjc.6602950
16. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L: Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.Ann Surg Oncol 2012,19(5):1508–1516. 10.1245/s10434-011-2108-2
17. Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, Ross MI, Buzdar AU, Hortobagyi GN, Singletary SE: Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.Ann Surg 1999,230(1):72–78. 10.1097/00000658-199907000-00011
18. Lebowitz PF, Eng-Wong J, Swain SM, Berman A, Merino MJ, Chow CK, Venzon D, Zia F, Danforth D, Liu E, Zujewski J: A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.Clin Cancer Res 2004,10(20):6764–6769. 10.1158/1078-0432.CCR-04-0976
19. Lee KS, Ro J, Nam BH, Lee ES, Kwon Y, Kwon HS, Chung KW, Kang HS, Kim EA, Kim SW, Shin KH, Kim SK: A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer.Breast Cancer Res Treat 2008,109(3):481–489. 10.1007/s10549-007-9672-y
20. Li Q, Jiang Y, Wei W, Yang H, Liu J: Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systemic review and meta-analysis of randomised controlled trials.PLoS One 2013, 8:e53403. 10.1371/journal.pone.0053403
21. Marchio C, Sapino A: The pathologic complete response open question in primary therapy.J Natl Cancer Inst Monogr 2011,2011(43):86–90. 10.1093/jncimonographs/lgr025
22. Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, Rodriguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacon C, Roset M, Anton A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, Lopez-Vega JM, Munoz M, Mel JR: Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.Ann Oncol 2006,17(8):1205–1212. 10.1093/annonc/mdl135
23. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L: Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.J Clin Oncol 2007,25(19):2650–2655. 10.1200/JCO.2006.08.2271
24. Mieog JS, van der Hage JA, van de Velde CJ: Preoperative chemotherapy for women with operable breast cancer.Cochrane Database Syst Rev 2007, 2:CD005002.
25. Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.J Clin Oncol 2006,24(11):1656–1664. 10.1200/JCO.2005.03.2755
26. Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M: Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil- epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.Breast Cancer Res Treat 2013,142(1):69–80. 10.1007/s10549-013-2691-y
27. O'Shaughnessy J: Clinical experience of capecitabine in metastatic breast cancer.Eur J Cancer 2002,38(Suppl 2):10–14.
28. O'Shaughnessy J, Paul D, Stokoe C, Pippen JL, Blum JL, Krekow L, Holmes FA, Vukelja S, Lindquist D, Sedlacek S: First efficacy results of a randomised, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer. In Proceedings of 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, Dec 8–12 2010. San Antonio, TX; 2009.
29. Peduzzi P, Concato J, Feinstein AR, Holford TR: Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates.J Clin Epidemiol 1995,48(12):1503–1510. 10.1016/0895-4356(95)00048-8
30. Penault-Llorca F, Abrial C, Raoelfils I, Cayre A, Mouret-Reynier MA, Leheurteur M, Durando X, Achard JL, Gimbergues P, Chollet P: Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.Hum Pathol 2008,39(8):1221–1228. 10.1016/j.humpath.2007.11.019
31. Precht LM, Lowe KA, Atwood M, Beatty JD: Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.Breast J 2010,16(4):362–368.
32. Recht A, Houlihan MJ: Axillary lymph nodes and breast cancer: a review.Cancer 1995,76(9):1491–1512. Publisher Full Text 10.1002/1097-0142(19951101)76:9<1491::AID-CNCR2820760902>3.0.CO;2-8
33. Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon A, Vielh P, Bourstyn E: Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.J Clin Oncol 2002,20(5):1304–1310. 10.1200/JCO.20.5.1304
34. Schott AF, Hayes DF: Defining the benefits of neoadjuvant chemotherapy for breast cancer.J Clin Oncol 2012,30(15):1747–1749. 10.1200/JCO.2011.41.3161
35. Semiglazov V, Eiermann W, Zambetti M, Manikhas A, Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, Baselga J, Gianni L: Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.Eur J Surg Oncol 2011,37(10):856–863. 10.1016/j.ejso.2011.07.003
36. Sharp DM, Walker MB, Chaturvedi A, Upadhyay S, Hamid A, Walker AA, Bateman JS, Braid F, Ellwood K, Hebblewhite C, Hope T, Lines M, Walker LG: A randomised, controlled trial of the psychological effects of reflexology in early breast cancer.Eur J Cancer 2010,46(2):312–322. 10.1016/j.ejca.2009.10.006
37. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.J Clin Oncol 2002,20(6):1456–1466. 10.1200/JCO.20.6.1456
38. Steger GG, Greil R, Jakesz R: Pathologic complete response in patient subgroups: An analysis of ABCSG-24, a phase III, randomised study of anthracycline- and taxane-based neo adjuvant therapy with or without capecitabine in early breast cancer.J Clin Oncol 2010, 28:74s. suppl 15s; abstr, 530
39. Vickers AJ, Altman DG: Statistics notes: analysing controlled trials with baseline and follow up measurements.BMJ 2001,323(7321):1123–1124. 10.1136/bmj.323.7321.1123
40. Villman K, Ohd JF, Lidbrink E, Malmberg L, Lindh B, Blomqvist C, Nordgren H, Bergh J, Bergstrom D, Ahlgren J: A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer.Eur J Cancer 2007,43(7):1153–1160. 10.1016/j.ejca.2007.02.002
41. von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kuhn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Untch M: Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.J Clin Oncol 2010,28(12):2015–2023. 10.1200/JCO.2009.23.8303
42. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.J Clin Oncol 2012,30(15):1796–1804. 10.1200/JCO.2011.38.8595
43. Walker LG, Anderson J, Heys S: Quality of life during primary chemotherapy: randomised controlled trial of CVAP and docetaxel.Ann Oncol 1998,9(Suppl 4):S16.
44. Walker LG, Heys SD, Walker MB, Ogston K, Miller ID, Hutcheon AW, Sarkar TK, Ah-See AK, Eremin O: Psychological factors can predict the response to primary chemotherapy in patients with locally advanced breast cancer.Eur J Cancer 1999,35(13):1783–1788. 10.1016/S0959-8049(99)00169-0
45. Walker LG, Green VL, Greenman J, Walker AA, Sharp DM: PNI and chronic malignant disease: cancer. In Human Psychoneuroimmunology. Edited by: Irwin M, Vedhara V. Oxford: Oxford University Press; 2005.
46. Walker LG, Eremin JM, Aloysius MM, Vassanasiri W, Walker MB, El-Sheemy M, Cowley G, Beer J, Samphao S, Wiseman J, Jibril JA, Valerio D, Clarke DJ, Kamal M, Thorpe GW, Baria K, Eremin O: Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer.BMC Cancer 2011, 11:179. doi: 110.1186/1471–2407–1111–1179 10.1186/1471-2407-11-179
47. Zigmond AS, Snaith RP: The hospital anxiety and depression scale.Acta Psychiatr Scand 1983,67(6):361–370. 10.1111/j.1600-0447.1983.tb09716.x